Results 191 to 200 of about 742,291 (286)

CDK4/6 Inhibitors and Curcumin Synergistically Suppress HER2− Breast Cancer via Lethal ROS and Inhibition of Metastasis

Cancer Science, EarlyView.
Schematic illustrating that CDK4/6 inhibitors combined with curcumin induce lethal ROS accumulation by disrupting redox balance, downregulating GPX4, and depleting glutathione, leading to DNA damage and lipid peroxidation. This oxidative stress triggers tumor cell death and suppresses EMT‐driven migration.
Chenyu Wang, Yiqin Zou, Chunyu Chang, Siyue Liu, Xiankun Ke, Liang Hu, Di Wang, Yukang Lu, Shiwen Luo, Sijian Huang, Yilan Hu, Wenqi Yu, Aiping Deng, Ming Yue, Jue Jiang   +14 more
wiley   +1 more source

PARP Inhibitors plus Anlotinib as Bridging Therapy for Armored CAR-T Cells in Ovarian Cancer Enhances Infiltration and Antitumor Efficacy. [PDF]

Adv Sci (Weinh)
Li H, Xiang M, Xu Q, Liu J, Jiao X, Mu W, Lv X, Tao K, Xu Y, Zhou D, Gong W, Yan D, Hu Y, Xu S, Zhao B, Li J, Gai Y, Hu G, Zhu L, Gao Q, Fang Y.   +20 more
europepmc   +1 more source

Real‐World Germline Variant Landscape and Clinical Management in Korean Patients Tested for Suspected Hereditary Cancer

Cancer Science, EarlyView.
In 5829 Korean patients undergoing hereditary cancer germline testing, 987 (16.9%) carried pathogenic/likely pathogenic variants. Post‐test management varied substantially across gene groups, while variant reclassification identified 46 additional carriers, underscoring the need for gene‐specific management and structured recontact.
Min‐Chae Kang, Ha‐Eun Lee, Sang‐Yoon Park, Seeyoun Lee, So‐Youn Jung, Myong Cheol Lim, Han‐Sung Kang, Chang Ahn Seol, Jun‐Ha Jang, Sang Myung Woo, Jae Young Joung, Wonyoung Choi, Sung Chan Park, Sun‐Young Kong   +13 more
wiley   +1 more source

PARPs and PARP inhibitors: molecular mechanisms and clinical applications. [PDF]

Mol Biomed
Wang F, Guo Z, Carr MJ, Shi W.
europepmc   +1 more source

Expanding the horizons of PARP inhibitors [PDF]

Nature Reviews Cancer, 2010
openaire   +2 more sources

Leveraging venetoclax‐induced autophagy to enhance AUTAC‐mediated Mcl1 degradation and overcome resistance in acute myeloid leukaemia

British Journal of Haematology, EarlyView.
Ahmed M. Elshazly, Nayyerehalsadat Hosseini, Janakiram R. Vangala, Xiaoyan Hu, Steven Grant, Senthil K. Radhakrishnan   +5 more
wiley   +1 more source

Methyl 4‐O‐Demethylbarbatate Destabilises HIF‐1α and Enhances Temozolomide Sensitivity in Glioma Cells

Cell Proliferation, EarlyView.
The lichen‐derived metabolite methyl 4‐O‐demethylbarbatate (Me‐4‐O‐DBA) suppresses glioma stemness, motility, and metabolic plasticity through inhibition of HIF‐1α signaling and synergistically enhances temozolomide activity, highlighting a potential strategy to target stemness‐driven therapeutic resistance in glioma.
Rui Zhou, Mücahit Varlı, Rundong Liu, Jieun Yu, Hyung‐Ho Ha, Jae‐Seoun Hur, Sang Kyum Kim, Hahyun Park, Hangun Kim   +8 more
wiley   +1 more source

Efficacy and safety of PARP inhibitors in older patients with advanced ovarian cancer: a systematic review and network meta-analysis. [PDF]

Front Oncol
Liang L, Yang B, Wu Y, Liu JL, Liu R, Sun L.   +5 more
europepmc   +1 more source

Glioblastoma and PARP inhibitors: the importance of patient selection to maximize therapeutic benefits. A critical review. [PDF]

Front Oncol
Dima G, Di Nunno V, Aprile M, Gatto L, Tosoni A, Argento CM, Margotti M, Bartolini S, Franceschi E.   +8 more
europepmc   +1 more source